In the Spotlight - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

In the Spotlight
Editors' Picks of Pharmaceutical Science & Technology Innovations

Pharmaceutical Technology
Volume 33, Issue 6, pp. 28

Editors' Picks of Pharmaceutical Science & Technology Innovations

Drugmakers never stop looking for components and equipment that will create therapies more quickly, more reliably, and more efficiently. The industry's need pushes pharmaceutical and biopharmaceutical manufacturing technology to evolve continually. This month's featured products are designed to improve the speed and flexibility of the pharmaceutical production line. Continental Disc's rupture discs can withstand harsh conditions. Thomas Engineering has unveiled a tablet coater designed to facilitate cleaning validation and reduce contamination. And Millipore's membrane adsorber can remove impurities at high salt concentrations.

Tablet coater provides flexibility


Accela-Cota Flex 500 tablet coater Thomas Engineering www.thomaseng.com
The Accela-Cota Flex 500 production-class tablet coater from Thomas Engineering (Hoffman Estates, IL) incorporates drums that can be removed and exchanged in 30 min without tools. This feature lets operators dedicate a drum to a particular product, thus facilitating cleaning validation and reducing risk of cross contamination. The tablet coater accepts drums of various sizes, allowing users to choose the right drum for the process they must perform. Removing the drums enables operators to clean the inside of the coater thoroughly. The machine's mixing baffles are also interchangeable.

Rupture disc withstands severe conditions


SanitRX MP rupture disc Continental Disc www.contdisc.com
Continental Disc (Liberty, MO) has added the MP unit to its SanitRX series of rupture discs. The product was designed for applications during which conditions frequently change between positive pressure and vacuum. The company moved the disc's score line from the contact side to the downstream side so that it is subject to less stress when pressure changes. The new position also improves the disc's cleanability. The disc can be cleaned or steamed in place.

The disc complies with the American Society for Mechanical Engineers's bioprocessing equipment criteria for process-side surface finish and fully traceable metal and elastomer materials. The component also is free of polishing compounds, release agents, and animal derivatives. The disc is appropriate for pressure-vessel applications such as autoclaves, fermenters, and heat exchangers.

Membrane adsorber uses nontraditional chemistry


ChromaSorb membrane adsorber Millipore www.millipore.com
The ChromaSorb solution is a single-use anion-exchange membrane adsorber from Millipore (Billerica, MA) designed to remove negatively charged impurities. The product has greater binding strength at high salt concentrations than traditional resins and current membranes, according to the company. This strength results from a primary-amine gel with a high charge density that coats the adsorber's base membrane. The gel provides many areas of contact for negatively charged impurities such as host-cell proteins and viruses to bind.

Because ChromaSorb devices can continue to bind at high salt concentrations, no product dilution is required. The ChromaSorb product is designed for flow-through applications at the polishing step of the purification of monoclonal antibodies and recombinant proteins.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here